Portal de Periódicos da CAPES

COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 TO DETECT BLADDER CANCER

1999; Lippincott Williams & Wilkins; Volume: 162; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(05)68076-7

1527-3792

Marta Sänchez‐Carbayo, Enrique Herrero, Julián Megías, Antonio Mira, Federico Soria,

Tissue Engineering and Regenerative Medicine

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 1999COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 * TO DETECT BLADDER CANCER MARTA SÁNCHEZ-CARBAYO, ENRIQUE HERRERO, JULIÁN MEGÍAS, ANTONIO MIRA, and FEDERICO SORIA MARTA SÁNCHEZ-CARBAYOMARTA SÁNCHEZ-CARBAYO , ENRIQUE HERREROENRIQUE HERRERO , JULIÁN MEGÍASJULIÁN MEGÍAS , ANTONIO MIRAANTONIO MIRA , and FEDERICO SORIAFEDERICO SORIA View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68076-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † IDL Biotech, Sollentuna, Sweden. , tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers. References 1 : Preventing recurrence and progression in superficial bladder cancer. Curr. Opin. Urol.1996; 6: 272. Crossref, Google Scholar 2 : Bladder cancer: natural history, tumor markers and early detection strategies. Sem. Surg. Oncol.1997; 13: 299. Crossref, Medline, Google Scholar 3 : Superficial bladder cancer: for how long should a tumor-free patient have check cystoscopies? Brit. J. Urol.1995; 75: 193. Crossref, Google Scholar 4 : The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer1987; 60: 1423. Crossref, Medline, Google Scholar 5 : Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low grade superficial bladder tumors. Amer. J. Path.1992; 140: 375. Medline, Google Scholar 6 : Results of a multicenter trial using BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol.1995; 154: 379. Link, Google Scholar 7 : Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J. Urol.1996; 155: 475. Link, Google Scholar 8 : Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol.1996; 156: 363. Link, Google Scholar 9 : Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol.1996; 156: 1280. Link, Google Scholar 10 : Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur. Urol.1997; 31: 163. Crossref, Medline, Google Scholar 11 : Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol.1998; 159: 394. Link, Google Scholar 12 : Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology1998; 52: 398. Crossref, Medline, Google Scholar 13 : A multicenter trial evaluation of the fibrin/fribrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol.1997; 158: 801. Link, Google Scholar 14 : Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol.1997; 158: 2098. Link, Google Scholar 15 : Initial evaluation of urinary bladder cancer antigen as a tumor marker for bladder cancer. J. Urol.1999; 161: 1110. Link, Google Scholar 16 : New methods for detection of bladder cancer. Sem. Urol. Oncol.1998; 16: 17. Medline, Google Scholar 17 : The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell1982; 31: 11. Crossref, Medline, Google Scholar 18 : Keratins as biochemical markers of epithelial differentiation. Trends Genet.1988; 4: 277. Crossref, Medline, Google Scholar 19 : The biochemistry of CYFRA 21-1 and other cytokeratin-tests. Scand. J. Clin. Lab. Invest1995; 221: 60. Crossref, Google Scholar 20 : Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J. Urol.1997; 158: 338. Link, Google Scholar 21 : Antigenicity of pooled human malignant and normal tissues by citoimmunological technique: presence of an insoluble, heatlabile tumor antigen. Int. Arch. Allergy1957; 10: 153. Crossref, Google Scholar 22 : Identification of a nuclear protein matrix. Biochem. Biophys. Res. Comm.1974; 60: 1410. Crossref, Medline, Google Scholar 23 : Bladder cancer-associated nuclear matrix proteins. Cancer Res.1996; 56: 1690. Medline, Google Scholar 24 : Utilization of nuclear matrix proteins for cancer diagnosis. Crit. Rev. Eukaryot Gene Exp.1996; 6: 189. Crossref, Medline, Google Scholar 25 : Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta. Cytol.1993; 37: 163. Medline, Google Scholar From the Laboratorio de Marcadores Tumorales, Servicios de Análisis Clínicos and Urologia, Hospital General Universitario de Alicante, Alicante, Spain© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Zhu R, Zhou J, Liang P, Xiang X, Ran J, Xie T and Guo X (2022) Accuracy of cytokeratin 19 fragment in the diagnosis of bladder cancerBiomarkers in Medicine, 10.2217/bmm-2021-0754, VOL. 16, NO. 3, (197-216), Online publication date: 1-Feb-2022. Tabayoyong W and Kamat A (2018) Current Use and Promise of Urinary Markers for Urothelial CancerCurrent Urology Reports, 10.1007/s11934-018-0857-1, VOL. 19, NO. 12, Online publication date: 1-Dec-2018. Maas M, Walz S, Stühler V, Aufderklamm S, Rausch S, Bedke J, Stenzl A and Todenhöfer T (2018) Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancerExpert Review of Molecular Diagnostics, 10.1080/14737159.2018.1469979, VOL. 18, NO. 5, (443-455), Online publication date: 4-May-2018. Hakenberg O (2018) Urinmarker beim Blasenkarzinom Urinzytologie und Sedimentanalyse, 10.1007/978-3-662-55660-3_8, (135-152), . D'Costa J, Goldsmith J, Wilson J, Bryan R and Ward D A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder CancerBladder Cancer, 10.3233/BLC-160054, VOL. 2, NO. 3, (301-317) Huang Y, Chen J, Yan W, Zang D, Qin Q and Deng A (2015) Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21–1) for bladder cancer: a systematic review and meta-analysisTumor Biology, 10.1007/s13277-015-3352-z, VOL. 36, NO. 5, (3137-3145), Online publication date: 1-May-2015. Schmitz-Dräger B, Droller M, Lokeshwar V, Lotan Y, Hudson M, van Rhijn B, Marberger M, Fradet Y, Hemstreet G, Malmstrom P, Ogawa O, Karakiewicz P and Shariat S (2014) Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD ConsensusUrologia Internationalis, 10.1159/000369357, VOL. 94, NO. 1, (1-24), . Ecke T (2015) Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer Advances in Cancer Biomarkers, 10.1007/978-94-017-7215-0_18, (293-316), . Kamat A, Vlahou A, Taylor J, Hudson M, Pesch B, Ingersoll M, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell P, Palou J, Sanchez-Carbayo M and Schmitz-Dräger B (2014) Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancerUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2014.06.017, VOL. 32, NO. 7, (1069-1077), Online publication date: 1-Oct-2014. Olmsted I, Hassanein M, Kussrow A, Hoeksema M, Li M, Massion P and Bornhop D (2014) Toward Rapid, High-Sensitivity, Volume-Constrained Biomarker Quantification and Validation using Backscattering InterferometryAnalytical Chemistry, 10.1021/ac501355q, VOL. 86, NO. 15, (7566-7574), Online publication date: 5-Aug-2014. Xylinas E, Kluth L, Rieken M, Karakiewicz P, Lotan Y and Shariat S (2014) Urine markers for detection and surveillance of bladder cancerUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2013.06.001, VOL. 32, NO. 3, (222-229), Online publication date: 1-Apr-2014. Jeong S, Park Y, Cho Y, Kim Y and Kim H (2012) Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancerClinica Chimica Acta, 10.1016/j.cca.2012.08.018, VOL. 414, (93-100), Online publication date: 1-Dec-2012. Lamarca A and Barriuso J (2012) Urine Telomerase for Diagnosis and Surveillance of Bladder CancerAdvances in Urology, 10.1155/2012/693631, VOL. 2012, (1-7), . Satyam A, Singh P, Sharma M, Seth A and Sharma A (2011) CYFRA 21-1: A potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladderBiomarkers, 10.3109/1354750X.2011.582152, VOL. 16, NO. 5, (413-421), Online publication date: 1-Aug-2011. Karl A and Konety B (2010) Treatment of Superficial Bladder Cancer Evidence-Based Urology, 10.1002/9781444323146.ch31, (304-313) Sturgeon C, Duffy M, Hofmann B, Lamerz R, Fritsche H, Gaarenstroom K, Bonfrer J, Ecke T, Grossman H, Hayes P, Hoffmann R, Lerner S, Löhe F, Louhimo J, Sawczuk I, Taketa K and Diamandis E (2010) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric CancersClinical Chemistry, 10.1373/clinchem.2009.133124, VOL. 56, NO. 6, (e1-e48), Online publication date: 1-Jun-2010. Ecke T Tumor markers for bladder cancer: outlook for routine use 1LaboratoriumsMedizin, 10.1515/jlm.2010.021et, VOL. 34, NO. 2, (-) Ecke T Tumormarker beim Blasentumor: Aussichten für den klinischen Alltag / Tumor markers for bladder cancer: outlook for routine useLaboratoriumsMedizin, 10.1515/jlm.2010.021, VOL. 34, NO. 2, (77-86) Gaston K and Grossman H (2010) Proteomic Assays for the Detection of Urothelial Cancer The Urinary Proteome, 10.1007/978-1-60761-711-2_17, (303-323), . Vintizenko S, Slonimskaya Y, Usynin Y and Stukanov S (2009) UBC-test use in the capacity of urinary marker of bladder cancerBulletin of Siberian Medicine, 10.20538/1682-0363-2009-2-113-117, VOL. 8, NO. 2, (113-117) Van Tilborg A, Bangma C and Zwarthoff E (2008) Bladder cancer biomarkers and their role in surveillance and screeningInternational Journal of Urology, 10.1111/j.1442-2042.2008.02174.x, VOL. 16, NO. 1, (23-30), Online publication date: 1-Jan-2009. Babjuk M, Soukup V, Pešl M, Koštířová M, Drncová E, Smolová H, Szakacsová M, Getzenberg R, Pavlík I and Dvořáček J (2008) Urinary Cytology and Quantitative BTA and UBC Tests in Surveillance of Patients with pTapT1 Bladder Urothelial CarcinomaUrology, 10.1016/j.urology.2007.12.021, VOL. 71, NO. 4, (718-722), Online publication date: 1-Apr-2008. Bian W and Xu Z (2007) Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinomaInternational Journal of Urology, 10.1111/j.1442-2042.2007.01670.x, VOL. 14, NO. 2, (108-111), Online publication date: 1-Feb-2007. Campos-fernandes J, Descotes F, Andre J, Perrin P, Devonec M and Ruffion A (2007) Intérêt des marqueurs urinaires dans le diagnostic et le suivi des tumeurs urothéliales de vessieProgrès en Urologie, 10.1016/S1166-7087(07)92221-6, VOL. 17, NO. 1, (23-34), Online publication date: 1-Feb-2007. Hakenberg O (2007) Urinmarker und zellbasierte Nachweisverfahren beim Urothelkarzinom Urinzytologie, 10.1007/978-3-662-44779-6_9, (135-155), . Hakenberg O Urinmarker und zellbasierte Nachweisverfahren beim Urothelkarzinom Urinzytologie, 10.1007/978-3-540-31041-9_9, (135-155) Konety B (2006) Molecular markers in bladder cancer: A critical appraisalUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2005.11.023, VOL. 24, NO. 4, (326-337), Online publication date: 1-Jul-2006. Lokeshwar V, Habuchi T, Grossman H, Murphy W, Hautmann S, Hemstreet G, Bono A, Getzenberg R, Goebell P, Schmitz-Dräger B, Schalken J, Fradet Y, Marberger M, Messing E and Droller M (2005) Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markersUrology, 10.1016/j.urology.2005.08.064, VOL. 66, NO. 6, (35-63), Online publication date: 1-Dec-2005. Weikert S, Krause H, Wolff I, Christoph F, Schrader M, Emrich T, Miller K and Müller M (2005) Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancerInternational Journal of Cancer, 10.1002/ijc.21168, VOL. 117, NO. 2, (274-280), Online publication date: 1-Nov-2005. Hakenberg O, Fuessel S, Richter K, Froehner M, Oehlschlaeger S, Rathert P, Meye A and Wirth M (2004) Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinomaUrology, 10.1016/j.urology.2004.08.019, VOL. 64, NO. 6, (1121-1126), Online publication date: 1-Dec-2004. Barak V, Goike H, Panaretakis K and Einarsson R (2004) Clinical utility of cytokeratins as tumor markersClinical Biochemistry, 10.1016/j.clinbiochem.2004.05.009, VOL. 37, NO. 7, (529-540), Online publication date: 1-Jul-2004. Wu J (2004) Types of Circulating Tumor Markers and Their Clinical Applications Cancer Diagnostics, 10.1007/978-1-59259-791-8_4, (35-51), . Tinzl M and Marberger M (2003) Urinary Markers for Detecting Bladder CancerEAU Update Series, 10.1016/S1570-9124(03)00022-9, VOL. 1, NO. 2, (64-70), Online publication date: 1-Jun-2003. PAREKATTIL S, FISHER H and KOGAN B (2018) Neural Network Using Combined Urine Nuclear Matrix Protein-22, Monocyte Chemoattractant Protein-1 and Urinary Intercellular Adhesion Molecule-1 to Detect Bladder CancerJournal of Urology, VOL. 169, NO. 3, (917-920), Online publication date: 1-Mar-2003. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T and Pode D (2002) Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinomaCancer, 10.1002/cncr.10565, VOL. 94, NO. 11, (2914-2922), Online publication date: 1-Jun-2002. Babjuk M, Koštı́řová M, Mudra K, Pecher S, Smolová H, Pecen L, Ibrahim Z, Dvořáček J, Jarolı́m L, Novák J and Zima T (2002) Qualitative and Quantitative Detection of Urinary Human Complement Factor H-Related Protein (BTA stat and BTA TRAK) and Fragments of Cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as Markers for Transitional Cell Carcinoma of the BladderEuropean Urology, 10.1016/S0302-2838(01)00015-X, VOL. 41, NO. 1, (34-39), Online publication date: 1-Jan-2002. Böhle A, Brandau S, Durek C, Ardelt P and Kausch I (2002) Blasenkarzinom Molekularmedizinische Grundlagen von nicht-hereditären Tumorerkrankungen, 10.1007/978-3-642-56297-6_10, (291-328), . S�nchez-Carbayo M, Urrutia M, Gonz�lez de Buitrago J and Navajo J (2001) Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinomaCancer, 10.1002/1097-0142(20011201)92:11 3.0.CO;2-I, VOL. 92, NO. 11, (2820-2828), Online publication date: 1-Dec-2001. S�nchez-Carbayo M, Ciudad J, Urrutia M, Alejandro Navajo J and Orfao A (2001) Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinomaCancer, 10.1002/1097-0142(20011201)92:11 3.0.CO;2-T, VOL. 92, NO. 11, (2811-2819), Online publication date: 1-Dec-2001. van der Poel H and Debruyne F (2001) Can biological markers replace cystoscopy? An updateCurrent Opinion in Urology, 10.1097/00042307-200109000-00009, VOL. 11, NO. 5, (503-509), Online publication date: 1-Sep-2001. GIANNOPOULOS A, MANOUSAKAS T, GOUNARI A, CONSTANTINIDES C, CHOREMI-PAPADOPOULOU H and DIMOPOULOS C (2018) COMPARATIVE EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE BTA STAT TEST, NMP22 AND URINARY BLADDER CANCER ANTIGEN FOR PRIMARY AND RECURRENT BLADDER TUMORSJournal of Urology, VOL. 166, NO. 2, (470-475), Online publication date: 1-Aug-2001. S??NCHEZ-CARBAYO M, URRUTIA M, SILVA J, ROMAN?? R, DE BUITRAGO J and NAVAJO J (2001) COMPARATIVE PREDICTIVE VALUES OF URINARY CYTOLOGY, URINARY BLADDER CANCER ANTIGEN, CYFRA 21-1 AND NMP22 FOR EVALUATING SYMPTOMATIC PATIENTS AT RISK FOR BLADDER CANCERThe Journal of Urology, 10.1097/00005392-200105000-00015, (1462-1467), Online publication date: 1-May-2001. SÁNCHEZ-CARBAYO M, URRUTIA M, SILVA J, ROMANÍ R, DE BUITRAGO J and NAVAJO J (2018) COMPARATIVE PREDICTIVE VALUES OF URINARY CYTOLOGY, URINARY BLADDER CANCER ANTIGEN, CYFRA 21-1 AND NMP22 FOR EVALUATING SYMPTOMATIC PATIENTS AT RISK FOR BLADDER CANCERJournal of Urology, VOL. 165, NO. 5, (1462-1467), Online publication date: 1-May-2001.KONETY B and GETZENBERG R (2018) URINE BASED MARKERS OF UROLOGICAL MALIGNANCYJournal of Urology, VOL. 165, NO. 2, (600-611), Online publication date: 1-Feb-2001. Hans Boman, Hans Hedelin, Sten Holmäng (2009) Urine Tissue-Polypeptide-Specific Antigen (TPS) as a Marker for Bladder CancerScandinavian Journal of Urology and Nephrology, 10.1080/003655901750425828, VOL. 35, NO. 4, (270-274), Online publication date: 1-Jan-2001. GOLIJANIN D, SHAPIRO A and PODE D (2000) IMMUNOSTAINING OF CYTOKERATIN 20 IN CELLS FROM VOIDED URINE FOR DETECTION OF BLADDER CANCERThe Journal of Urology, 10.1097/00005392-200012000-00013, (1922-1925), Online publication date: 1-Dec-2000. GOLIJANIN D, SHAPIRO A and PODE D (2018) IMMUNOSTAINING OF CYTOKERATIN 20 IN CELLS FROM VOIDED URINE FOR DETECTION OF BLADDER CANCERJournal of Urology, VOL. 164, NO. 6, (1922-1925), Online publication date: 1-Dec-2000. Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M and Pycha A (2000) Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladderUrology, 10.1016/S0090-4295(00)00664-6, VOL. 56, NO. 2, (228-231), Online publication date: 1-Aug-2000. Martínez E and Morote J (2000) Marcadores tumorales del cáncer vesicalMedicina Clínica, 10.1016/S0025-7753(00)71302-9, VOL. 114, NO. 10, (378-379), Online publication date: 1-Jan-2000. Volume 162Issue 6December 1999Page: 1951-1956 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Keywordstissue polypeptide antigentumor markers, biologicalbladder neoplasmsurineMetricsAuthor Information MARTA SÁNCHEZ-CARBAYO More articles by this author ENRIQUE HERRERO More articles by this author JULIÁN MEGÍAS More articles by this author ANTONIO MIRA More articles by this author FEDERICO SORIA More articles by this author Expand All Advertisement PDF downloadLoading ...